Please login to the form below

Not currently logged in
Email:
Password:

German partners find diabetes biomarker

Helmholtz Zentrum München and Boehringer Ingelheim have identified a biomarker for diabetes-relevant protein

Helmholtz Zentrum München and Boehringer Ingelheim have jointly identified a biomarker for diabetes-relevant protein.

The indicator will enable the pre-clinical testing of FABP4 inhibitors, therefore facilitating the selection of potentially effective substances. Studies on human subjects and mouse models show that the FABP4 protein could be a potential target protein for new drugs to treat diabetes mellitus and atherosclerosis.

The biomarker was found through the use of lipidomics and metabolomics. Scientists at the Helmholtz Zentrum München were the first to use the modern lipidomics technologies to successfully identify such functionally relevant biomarkers for FABP4.

Boehringer Ingelheim provided the necessary biological and indication-specific knowledge; the Helmholtz Zentrum München contributed expertise in metabolomics and bioinformatics.

The development of the biomarker for FABP4 was the pilot project for the collaborative research venture to identify functional biomarkers.

19th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...